ENANTA PHARMACEUTICALS INC Income Statement
ENTA|13 years of annual SEC 10-K data (FY2013-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 13 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$79M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$137M
FY2025
Net Income
-$134M
FY2025
ENANTA PHARMACEUTICALS INC reported $79M in revenue and $134M in net loss for FY2025. Revenue has grown at a 5.5% compound annual rate over the past 12 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M | $102.8M | $88.3M | $160.9M | $47.7M | $32.1M | $41.7M | $41.9M |
| SG&A Expense | $52.9M | $45.5M | $32.5M | $27.4M | $26.2M | $23.4M | $20.7M | $17.0M | $13.5M | $10.0M | $6.2M | $5.3M | $5.0M |
| R&D Expense | $163.5M | $164.5M | $174.1M | $136.8M | $142.2M | $94.9M | $57.5M | $40.5M | $23.2M | $18.7M | $16.8M | $15.1M | $11.5M |
| Operating Income | -$137.2M | -$123.8M | -$109.6M | -$41.6M | $36.7M | $88.3M | $24.6M | $30.8M | $124.1M | $19.0M | $9.0M | $21.3M | $25.3M |
| Interest Expense | - | - | $0 | - | - | - | - | - | $8.0K | $18.0K | $31.0K | $31.0K | $3.2M |
| Income Tax | $2.8M | -$433.0K | -$28.6M | $1.1M | -$826.0K | $21.2M | $9.2M | $10.9M | $46.5M | -$15.2M | $0 | $0 | $0 |
| Net Income | -$133.8M | -$121.8M | -$79.0M | -$36.2M | $46.4M | $72.0M | $17.7M | $21.7M | $79.0M | $34.4M | $9.6M | $21.4M | $23.3M |
| EPS (Basic) | -$6.38 | -$5.91 | -$3.92 | -$1.81 | $2.37 | $3.74 | $0.93 | $1.14 | $4.23 | $1.88 | -$0.67 | $1.26 | $1.40 |
| EPS (Diluted) | -$6.38 | -$5.91 | -$3.92 | -$1.81 | $2.21 | $3.48 | $0.91 | $1.13 | $4.09 | $1.80 | -$0.67 | $1.13 | $1.32 |
| Shares Outstanding | 21.2M | 21.1M | 20.8M | 20.2M | 20.1M | 19.7M | 19.4M | 19.1M | 19.0M | 18.7M | 18.6M | 17.9M | 1.1M |
| Operating Margin | -173.2% | -143.7% | -112.9% | -34.0% | 17.9% | 42.8% | 23.9% | 34.9% | 77.2% | 39.8% | 28.2% | 51.0% | 60.4% |
| Profit Margin | -168.9% | -141.3% | -81.4% | -29.5% | 22.6% | 34.8% | 17.2% | 24.6% | 49.1% | 72.1% | 30.0% | 51.3% | 55.7% |